Policy & Regulation
Alvotech raises USD165m in public offering and private placement
19 June 2026 - Biotechnology company Alvotech (NASDAQ:ALVO) announced on Thursday the closing of its underwritten public offering of 26,066,667 of its ordinary shares at an offering price of USD3.75 p...
Oncoinvent reports recruitment milestone in Phase 2 study of Radspherin in ovarian cancer
19 June 2026 - Oncoinvent ASA (Euronext Growth Oslo:ONCIN), a Norway-based clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, announced on Thursday that its...
Nortiva Bio launches to develop long-acting oral medicines using LYNX platform
18 June 2026 - Nortiva Bio Inc announced on Thursday its launch as a clinical-stage biopharmaceutical company focused on developing long-acting oral medicines using its proprietary LYNX drug delivery ...
FDA accepts Genentech application for Lunsumio and Polivy combination in large B-cell lymphoma
18 June 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), said on Thursday that the US Food and Drug Administration (FDA) has accepted its supplemental...
Ananda Pharma reports Phase 1 pharmacokinetic study results for MRX1
18 June 2026 - Ananda Pharma Limited, a UK pharmaceutical company developing regulatory approved cannabidiol medicines to treat complex, chronic conditions, announced on Wednesday the completion of it...
NMD Pharma reports further data from Phase 2a study of ignaseclant
18 June 2026 - NMD Pharma A/S, a Denmark-based clinical-stage biotechnology company, announced on Wednesday that further safety and efficacy data from its Phase 2a SYNAPSE-CMT exploratory study evalua...